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Insulin-stimulated glucose uptake throughGLUT4 plays a pivotal role inmaintaining normal blood glucose levels. Glucose transport throughGLUT4
requires both GLUT4 translocation to the plasma membrane and GLUT4 activation at the plasma membrane. Here we report that a cell-permeable
phosphoinositide-binding peptide, which induces GLUT4 translocation without activation, sequestered PI 4,5-P2 in the plasma membrane from its
binding partners. Restoring PI 4,5-P2 to the plasma membrane after the peptide treatment increased glucose uptake. No additional glucose transporters
were recruited to the plasma membrane, suggesting that the increased glucose uptake was attributable to GLUT4 activation. Cells overexpressing
phosphatidylinositol-4-phosphate 5-kinase treated with the peptide followed by its removal exhibited a higher level of glucose transport than cells
stimulated with a submaximal level of insulin. However, only cells treated with submaximal insulin exhibited translocation of the PH-domains of the
general receptor for phosphoinositides (GRP1) to the plasmamembrane. Thus, PI 4,5-P2, but not PI 3,4,5-P3 converted from PI 4,5-P2, induced GLUT4
activation. Inhibiting F-actin remodeling after the peptide treatment significantly impaired GLUT4 activation induced either by PI 4,5-P2 or by insulin.
These results suggest that PI 4,5-P2 in the plasma membrane acts as a second messenger to activate GLUT4, possibly through F-actin remodeling.
© 2006 Elsevier B.V. All rights reserved.Keywords: GLUT4; Glucose transport; PI 4,5-P2; F-actin1. Introduction
Insulin stimulates glucose uptake into adipose tissues and ske-
letal muscle through the glucose transporter GLUT4. In type 2
diabetes, this process is frequently impaired, resulting in abnormal
glucose homeostasis [1,2]. Thus, identifying themolecular basis of
GLUT4-mediated glucose uptake stimulated by insulin is crucial in
finding a countermeasure to type 2 diabetes.
Multiple steps that are regulated by insulin lead to transport of
glucose through GLUT4 [3–6]. First, insulin stimulation induces
translocation ofGLUT4-containing vesicles from the cytoplasm to
the plasma membrane by a process that requires an intact cyto-
skeleton [7–9]. Next, insulin stimulation provokes membrane
fusion of GLUT4-containing vesicles with the plasma membrane,Abbreviations: PI-4,5-P2, phosphatidylinositol 4,5-bisphosphate; PI 3,4,5-
P3, phosphatidylinositol 3,4,5-trisphosphate; GLUT, glucose transporter; PIP-
kinase, phosphatidylinositol phosphate-kinase; PH-domains, pleckstrin homol-
ogy domains; DMSO, dimethyl sulfoxide
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doi:10.1016/j.bbamcr.2006.05.012inserting GLUT4 in the plasma membrane so that GLUT4 faces
both the inside and outside of the cells [10,11]. Coincident with
membrane insertion, insulin stimulates SNARE complex forma-
tion to provoke the membrane fusion step, which is inhibited by
wortmannin suggesting a role for inositol lipids produced by the
activity of PI 3-kinase [12,13]. Translocation and proper insertion
of GLUT4 into the plasma membrane is necessary for insulin-
stimulated glucose uptake, but an inconsistency between GLUT4
translocation/insertion and glucose uptake has been observed [14–
27], suggesting that an additional step of GLUT4 activationwithin
the plasma membrane may also be required. For instance, when
insulin-stimulated glucose uptake was completely inhibited by
wortmannin, GLUT4 insertion into the plasma membrane sti-
mulated by insulinwas only partially blocked [13,26].On the other
hand, the increased binding of impermeant glucose analogues,
such as ATB-BMPA, to the plasma membrane after insulin sti-
mulation was reported to match the increased glucose uptake
[28,29], supporting a model that GLUT4 translocation/insertion is
necessary and sufficient for glucose uptake. However, ATB-
BMPA binds to the exofacial glucose binding site of GLUT4 that
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amount of GLUT4 exposed at the cell surface detected by this
method reflects not only a recruitment of GLUT4 to the cell
surface but also an increase in the fraction ofGLUT4 in the plasma
membrane that has changed from a ‘closed’ form to an ‘open’ form
required to transport glucose. Thus, the discrepancy between
GLUT4 translocation/insertion and glucose uptake implicates an
additional step, activation of the glucose transport function of
GLUT4, to regulate glucose transport by insulin.
Activating the glucose transport function of GLUT4 after trans-
location and insertion into the plasma membrane is also consistent
with studies showing insulin-independent pathways to insert
GLUT4 in the membrane without allowing glucose uptake. In
one recent observation, a cell-permeable phosphoinositide-binding
peptide (PBP10) induced GLUT4 translocation to the plasma
membrane, thereby properly inserting GLUT4 into the plasma
membrane. However, no glucose uptake was observed without
additional insulin stimulation [30]. Treating adipocytes with cyto-
chalasin B after insulin stimulation decreases insulin-stimulated
glucose uptake, since cytochalasin B blocks the glucose-binding
site of GLUT4 and inhibits the glucose transport ability of GLUT4
[31,32]. On the other hand, PBP10 treatment of 3T3-L1 adipocytes
that were pretreated with insulin did not affect insulin-stimulated
glucose uptake [30]. Therefore, an inability of PBP10 to increase
glucose uptake is not due to an occlusion of GLUT4 by PBP10.
Instead, these previous observations indicate that GLUT4 trans-
location/insertion andGLUT4 activation are separate events.While
insulin stimulation induces both, resulting in increased glucose
uptake, PBP10 treatment can induce GLUT4 translocation/in-
sertion, but not GLUT4 activation. In our previous study, 3T3-L1
adipocytes that were pretreated with PBP10, which had the inactive
form of GLUT4 in the plasma membrane, started to increase
glucose uptake after subsequent insulin stimulation more quickly
than cells stimulated by insulin without PBP10 pretreatment. Thus,
insulin stimulation caused GLUT4 activation at the plasma mem-
brane after completing translocation. However, at later time points
after adding insulin, glucose uptake in cells not pretreated with
PBP10 caught up with that in cells pretreated with PBP10, and
surpassed it thereafter [30]. These observations suggest that PBP10
treatment not only lacks the ability to activate GLUT4, but also has
an inhibitory effect on insulin-induced GLUT4 activation and
prevents GLUT4 from its full activation by insulin.
Although the molecular mechanism of the cellular events
caused by PBP10 treatment is still unclear, the available in vitro
and cellular data suggest that PBP10 binds to phosphoinositides
[33,34]. In an attempt to identify the mechanism of GLUT4
activation, we particularly focused on phosphoinositide signa-
ling at the plasma membrane where, in our previous study,
GLUT4 was activated [30].
Mammalian cells have multiple types of phosphoinositides that
are phosphorylated at the 3′, 4′, or 5′ positions of the inositol ring,
singly or in combinations. Depending on which position(s) in the
inositol ring is (are) phosphorylated, each phosphoinositide exhibits
specific cellular functions and binds specific ligands at its specific
subcellular location [35–37]. PI 4,5-P2 is found abundantly in the
plasma membrane and has been reported to be involved in
regulating the actin cytoskeleton, membrane trafficking, and ionchannel activity at the plasma membrane [38], which led us to
investigate an involvement of PI 4,5-P2 in GLUT4 activation at the
plasma membrane.
Here we report that PI 4,5-P2 in the plasma membrane is
sequestered from its binding partners in the presence of PBP10. PI
4,5-P2 replenished after PBP10 treatment, without being phos-
phorylated into PI 3,4,5-P3, inducedGLUT4 activation, which was
significantly impaired by inhibiting F-actin remodeling. Thus, these
results suggest that PI 4,5-P2 functions as a second messenger in
GLUT4 activation, presumably by regulating F-actin remodeling.
2. Materials and methods
2.1. Materials
PBP10 and its control peptide were synthesized as described previously [34].
Recombinant adenovirus for expressing the PH-domain of the general receptor for
phosphoinositides (GRP1) tagged with EGFP, anti-GLUT1 antibody and anti-
GLUT4 antibody were generous gifts from Dr. Morris J. Birnbaum. Plasmids for
expressing the PH-domain of PLCδ1 taggedwithEGFP and recombinant adenovirus
for expressing Myc-tagged human type 1α phosphatidylinositol 4-phosphate 5-
kinase were generous gifts from Dr. Helen L. Yin. Anti-Myc antibodies were
purchased from Cell Signaling (Beverly, MA). Control IgG, Alexa Fluor-labeled
secondary antibodies, latrunculin A and jasplakinolide were purchased from
Molecular Probes (Eugene, OR). 2-deoxy-D-[3H]glucose and 3-O-methy-D-[3H]
glucose were purchased from Amersham Biosciences (Piscataway, NJ). BODIPY
TR-XC6PI 3-P andBODIPYTR-XC6PI 4,5-P2were purchase fromEchelon (Salt
LakeCity, UT).All other reagents from commercial sourceswere of analytical grade.
2.2. Cell culture
3T3-L1 fibroblasts were maintained and induced to differentiate into adi-
pocytes as described previously [30]. The experiments were conducted 7–9 days
after inducing differentiation, when > 90% of cells expressed the adipocyte
phenotype to accumulate lipid droplets. 3T3-L1 adipocytes were serum starved
overnight before each experiment. To express the PH-domain of PLCδ1, cells were
electroporated as described previously [39]. Carrier-mediated phosphoinositide
delivery was conducted according to the manufacturer's instructions.
2.3. Immunostaining and microscopy
Cells were fixed and immunostained as described previously [30]. Images were
acquired by a Delta Vision system (Applied Precision, Issaquah, WA) and decon-
volved by SoftWoRx (Applied Precision). Membrane sheets were prepared and
immunostained for GLUT4. The membrane sheets were identified by staining them
with fluorescently-labeled concanavalin A. Images of GLUT4 in membrane sheets
were obtained by a Leica DM-IRBE2 microscope and quantified by Openlab (Im-
provision, Lexington, MA) as described previously [30]. To quantify the amount of
the HA-tag exposed to the extracellular surface, cells expressing HA-GLUT4-EGFP
were immunostained for theHA-tagwithout permeation as described previously [40].
Fluorescence intensity for both the HA-tag and EGFP was counted. To measure the
background fluorescence, control IgG was used instead of anti-HA antibodies. The
expression level of HA-GLUT4-EGFP in each cell was calibrated by dividing the
fluorescence intensity of the HA-tag by the fluorescence intensity of EGFP.
2.4. Glucose transport assay
3T3-L1 adipocytes plated in 24-well culture dishes were serum-starved as
indicated above, and incubated in KRP buffer (128 mM NaCl, 4.7 mM KCl,
1.25 mM CaCl2, 1.25 mM MgSO4, 5 mM sodium phosphate, pH 7.4) for an
additional 1 h prior to each treatment. The assay was initiated by adding 2-deoxy-D-
[3H]glucose or 3-O-methyl-D-[3H ]glucose (0.5 μCi/sample, 0.1 mmol), incubated at
37 °C for 4 min or for 1 min, respectively, and was terminated by washing the cells
once with ice-cold KRP buffer containing 0.3 mMphloretin and then twice with ice-
cold KRP buffer. The cells were then solubilized in 0.1% SDS, and the incorporated
radioactivity was determined by scintillation counting.
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3.1. PBP10 sequesters PI 4,5-P2 from its binding partners
In our previous study, a cell-permeable phosphoinositide-bin-
ding peptide, PBP10, induced GLUT4 translocation to the plasma
membrane and insertion into the plasma membrane without activa-
ing the glucose transport activity of GLUT4 in 3T3-L1 adpocytes
[30]. To elucidate the molecular mechanism of the cellular eventsFig. 1. PBP10 sequesters PI 4,5-P2 from its binding partners. The PH-domain of PLCδ1 ta
in Materials and methods. Cells were left untreated or treated either with 40 μM control p
PBP10, cellswerewashedwith amediumwithout PBP10 and incubated for 20minwith th
mediumwas replaced with the one supplemented with either BODIPYTR-XC6 PI 3-P o
the presence of exogenous phosphoinositide for 5 min. (A) Each Panel shows the subcellu
sections through themiddle of the cells. Representative images are shown fromone experi
cells untreated and treatedwith PBP10 shown inA, the fluorescent intensity across thewhi
membrane relative to the cytosol was measured from the line profile data of fluorescence i
from each cell, as shown in B. For the plasma membrane, the highest intensity in the plasm
two values from each cell. These two values were averaged for each cell. For the cytosol,
average values±S.E. obtained from three independent experiments, in which 10 cells wcaused by PBP10, changes in the availability of PI 4,5-P2 for its
binding partners were monitored. To this end, we expressed EGFP-
tagged PH-domains of PLCδ1, known to bind PI 4,5-P2 [41,42] in
3T3-L1 adipocytes. As shown in Fig. 1, in cells treated with a
control rhodamine B-labeled peptide (RhoB-QRL), which is cell-
permeable but does not bind phosphoinositide [34], the PH-domain
was targeted to the plasmamembrane.When cells were treatedwith
PBP10, a rhodamine B-labeled cell-permeable phosphoinositide-
binding peptide derived from a phosphoinositide-binding region inggedwithEGFPwas expressed in 3T3-L1 adipocytes by electroporation as described
eptide (RhoB-QRL) for 15 min, or with 40 μMPBP10 for 15 min. For washing out
emedium. For replenishing exogenous phosphoinositides after PBP10 treatment, the
r BODIPYTR-XC6 PI 4,5-P2 along with its shuttle carriers. Cells were incubated in
lar distribution of EGFP signal. Images were taken by deconvolution microscopy in
ment. Similar results were obtained from two other independent experiments. (B) For
te lineswas plotted as a line profile. (C) The fluorescence intensity ratio of the plasma
ntensity across cells as described previously [41,65]. Line profile data were obtained
a membrane was adopted each time a line crosses the plasma membrane, obtaining
the intensity of each pixel across a line in the cytosol of each cell was averaged. The
ere counted for each treatment, are shown. N.S., not significant.
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membrane. However, a plasma membrane localization of the PH-
domain was significantly restored either by removing PBP10 or by
addition of exogenous PI 4,5-P2, but not PI 3-P (Fig. 1C). These
results suggest that PBP10 can sequester PI 4,5-P2 from its binding
partners, but either a removal of PBP10 or a replenishment of PI
4,5-P2 makes PI 4,5-P2 available for PH-domains again.
3.2. Combining PBP10 treatment and replenishing PI 4,5-P2
increase glucose uptake
Since PBP10 pretreatment partially inhibitedGLUT4 activation
by insulin in our previous study [30], and PBP10 sequestered PI
4,5-P2 from its binding partners, by amechanism that was reversedFig. 2. Replenishing PI 4,5-P2 after PBP10 treatment increases glucose uptake. (A) 3T3-
Then the medium was replaced with the one supplemented either with shuttle carrier only
incubated for 5 min. 2-deoxy-D-glucose uptake was measured. Data are mean±S.E., and a
4,5-P2 or PBP10. *p<0.05 versus control cells. (B) 3T3-L1 adipocytes were infected with
level similar to its endogenous homologue (left panel) or at a level 10 times higher than the e
taken by deconvolutionmicroscopy in sections through themiddle of the cells. A represent
the PH-domain of PLCδ1 tagged with EGFP (C) or 3T3-L1 adipocytes (D) were infected
human type 1α PIP-kinase (PIPK). Cells were then either left untreated or treated with 40
plasmamembrane relative to that in the cytosolwasmeasured, as described in Fig. 1C. The
deoxy-D-glucose uptake was measured. Data are mean±S.E., and are expressed as fold
untreated. N.S., not significant. (E) 3T3-L1 adipocytes were infected either with control La
PIP-kinase (square). Cells were treated with 40 μMPBP10 for 15min, washedwith the me
wasmeasured. Data aremean±S.E., and are expressed as fold increases of glucose uptake
L1 adipocytes were infected either with control LacZ adenovirus or with recombinant ade
untreated or treatedwith 1 nM insulin, 10 nM insulin orwith 40μMPBP10 for 15min. For
for additional 20min. 3-O-methyl-D-glucose uptakewasmeasured. Data aremean±S.E., a
adenovirus and left untreated. *p<0.05 versus cells stimulated with 1 nM insulin. For paeither by washing out PBP10 or by replenishing PI 4,5-P2 (Fig. 1),
we investigated the effect of replenishing PI 4,5-P2 after PBP10
pretreatment on glucose uptake. For this purpose, we first mea-
sured 2-deoxy-D-glucose uptake in 3T3-L1 adipocytes treated with
PBP10 followed by a delivery of exogenous PI 4,5-P2. As shown
in Fig. 2A, delivering PI 4,5-P2 itself did not affect 2-deoxy-D-
glucose uptake. However, when cells were pretreated with PBP10
to have inactive GLUT4 in the plasma membrane, exogenous PI
4,5-P2 significantly increased 2-deoxy-D-glucose uptake.
The effect of replenishing PI 4,5-P2 was also tested by overex-
pressing human type Iα phosphatidylinositol 4-phosphate 5-kinase
(PIP-kinase), a lipid kinase that synthesizes PI 4,5-P2 from PI 4-P,
by adenovirus-mediated gene transfer. Kanzaki et al. have reported
that type I PIP-kinase overexpression in 3T3-L1 adipocytes led toL1 adipocytes were either left untreated(−) or treated with 40 μM PBP10 for 15 min.
or with a mixture of shuttle carrier and BODIPY TR-X C6 PI 4,5-P2, and cells were
re expressed as fold increases of glucose uptake in control cells without exogenous PI
a recombinant adenovirus that expresses myc-tagged human type 1α PIP-kinase at a
ndogenous homologue (right panel). Cells were stained for theMyc-tag. Imageswere
ative image for each expression is presented. (C andD) 3T3-L1 adipocytes expressing
either with control LacZ adenovirus or with recombinant adenovirus for expressing
μMPBP10 for 15 min. In C, the fluorescence intensity ratio of the PH-domain in the
average value±S.E. obtained from three independent experiments are shown. InD, 2-
increases of glucose uptake in control cells infected by control adenovirus and left
cZ adenovirus (circle) or with recombinant adenovirus for expressing human type 1α
dium and incubated in the medium for the indicated times. 2-deoxy-D-glucose uptake
in control cells infected by control adenovirus and left untreated with PBP10. (F) 3T3-
novirus for expressing human type 1α PIP-kinase (PIPK). Cells were then either left
washing out PBP10, cellswerewashedwith themediumand incubated in themedium
nd are expressed as fold increases of glucose uptake in control cells infected by control
nels A, D–F, similar results were obtained from two other independent experiments.
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and an accumulation of GLUT4 in the plasma membrane due to
inhibition ofGLUT4endocytosis [43].However,when human type
Iα PIP-kinase was expressed at a low level, similar to that of
endogenous mouse type Iβ PIP-kinase (a homologue of human
type Iα PIP-kinase), forced expression of PIP-kinase did not induce
vacuole formation or accumulate GLUT4 in the plasma membrane
(Fig. 2B, left panel, and Fig. 3A). In these cells, the exogenous PIP-
kinase was mainly targeted to the plasma membrane (Fig. 2B),
where GLUT4 activation was observed in our previous study [30].
On the other hand, when human type Iα PIP-kinase was over-
expressed at a level approximately 10 times higher than that of
endogenous PIP-kinase, the exogenous PIP-kinase not only loca-
lized in the plasma membrane but also coated large vacuoles as
reported previously (Fig. 2B, right panel) [43]. Thus, a low level
expression of exogenous PIP-kinase was adopted in the experi-
ments thereafter. A low level overexpression of PIP-kinase, which
was targeted to the plasma membrane, significantly restored the
plasmamembrane localization of the PH-domain of PLCδ1 even in
the presence of PBP10 (Fig. 2C). Thus, exogenous PIP-kinase
replenished PI 4,5-P2 in the plasma membrane.
We next looked at the effect of combining PIP-kinase over-
expression and PBP10 treatment on glucose uptake.Neither PBP10
treatment nor human type Iα PIP-kinase-overexpression alone
increased 2-deoxy-D-glucose uptake (Fig. 2D). In contrast, 3T3-L1
adipocytes that overexpressed PIP-kinase significantly increased 2-
deoxy-D-glucose uptake after PBP10 treatment. Consistent with the
hypothesis that PI 4,5-P2 may need to be resynthesized or liberated
at the plasma membrane in order to activate GLUT4, glucose
uptake could also be restored by washing out PBP10 after GLUT4
was delivered to the plasma membrane. As shown in Fig. 2E, in
adipocytes transfectedwith control adenovirus,washing out PBP10
had a tendency to increase 2-deoxy-D-glucose uptake, but the
increase was not statistically significant. However, PIP-kinase-
overexpressing cells exhibited a significantly enhanced 2-deoxy-D-
glucose uptake at all time points over control adenovirus-transfec-
ted cells. In PIP-kinase-overexpressing cells, washing out PBP10
increased 2-deoxy-D-glucose uptake up to 4.8 fold over control
cells infected by control adenovirus and left untreated.
Increased glucose uptake by PBP10 treatment followed by its
removal in PIP-kinase overexpressing cells was also observed by
measuring 3-O-methyl-D-glucose uptake, instead of measuring 2-
deoxy-D-glucose uptake, confirming an increased glucose trans-
port activity in these cells (Fig. 2F). The increase in glucose uptake
in these cells was lower than that shown in Fig. 2E, presumably
due to multiple passages, but still significantly higher than that in
cells stimulated with a submaximal level of insulin.
Thus, PBP10 treatment followed by a replenishment of PI
4,5-P2 leads to an increased glucose uptake.
3.3. Increased glucose uptake by PI 4,5-P2 replenishment is
not attributable to recruitment of GLUT4 or GLUT1
The increased glucose uptake in 3T3-L1 adipocytes treated
with PBP10 and replenished with PI 4,5-P2 can be achieved
by newly recruiting and activating GLUT4, instead of
activating GLUT4 that is already distributed in the plasmamembrane by PBP10 treatment. This could also be achieved
by recruiting to the plasma membrane another type of glucose
transporter, GLUT1, which is abundantly expressed in 3T3-
L1 adipocytes.
To examine these possibilities, we quantified the amount
of GLUT4 and GLUT1 in the plasma membrane. As shown
in Fig. 3A, both insulin stimulation and PBP10 treatment
increased the amount of GLUT4 in plasma membrane sheets
by inducing GLUT4 translocation. PIP-kinase overexpression
did not cause GLUT4 translocation. Treating PIP-kinase-
overexpressing cells with PBP10 followed by its removal did
not increase GLUT4 content in the membrane sheets
compared to addition of PBP10 to control cells, but did
significantly increase glucose uptake (Fig. 2E). The amount
of GLUT4 in membrane sheets made from PBP10-treated
cells was not changed when PBP10 was washed out from
either control or PIP-kinase-overexpressing cells (data not
shown).
A direct relation between GLUT4 present in membrane sheets
and glucose uptake rate is complicated by evidence that GLUT4-
containing vesicles tethered to but not inserted in the plasma
membrane stay connected during membrane sheet preparation
[44,45]. To evaluate the effect of PI 4,5-P2 replenishment on
recruiting GLUT4 that is capable of glucose transport, we ex-
pressed HA-GLUT4-EGFP in 3T3-L1 adipocytes and quantified
the amount of theHA-tag exposed at the cell surface. This epitope-
tagged GLUT4 has been reported to translocate identically to
endogenous GLUT4 when cells are stimulated with insulin [46].
In accordance with data for endogenous GLUT4 detected in
membrane sheets, HA-GLUT4-EGFP was detected on the cell
surface after PBP10 treatment, indicating GLUT4 translocation
and insertion to the plasma membrane (Fig. 3B). PIP-kinase-
overexpression itself did not expose HA-GLUT4-EGFP at the cell
surface. Treating PIP-kinase-overexpressing cells with PBP10
followed by its removal, which exhibited a significant increase in
glucose uptake, induced a comparable level of the HA-tag ex-
posed at the cell surface as PBP10 treatment only. Thus, the
increased glucose uptake was not due to a de novo recruitment of
GLUT4. As reported previously [30], PBP10 treatment failed to
translocate GLUT1 (Fig. 3C). Neither PIP-kinase overexpres-
sion nor a combination of PIP-kinase overexpression and PBP10
treatment followed by its removal caused GLUT1 translocation.
These results suggest that the increased glucose uptake
observed in PIP-kinase overexpressing cells treated with
PBP10 followed by its removal is attributable to an activation
of GLUT4 but not GLUT1 in the plasma membrane.
3.4. PI 4,5-P2 functions as a second messenger to
activate GLUT4
3T3-L1 adipocytes overexpressing PIP-kinase exhibited
GLUT4 activation after PBP10 treatment and its removal,
presumably by supplying more PI 4,5-P2. Since GLUT4
activation, as well as GLUT4 translocation, downstream of
insulin stimulation requires PI 3-kinase activation [30],
GLUT4 activation in PIP-kinase overexpressing cells may
have been due to a conversion of PI 4,5-P2 supplied by the
894 M. Funaki et al. / Biochimica et Biophysica Acta 1763 (2006) 889–899overexpressed PIP-kinase into PI 3,4,5-P3. To test this
possibility, we looked at the subcellular distribution of the
PH-domain of GRP1, whose translocation to the plasma
membrane indicates PI 3,4,5-P3 production [47]. As shown inFig. 4, insulin stimulation even at a submaximal level (1 nM)
translocated the PH-domain of GRP1 to the plasmamembrane. On
the contrary, PIP-kinase-overexpressing cells treated with PBP10
followed by its removal failed to translocate the PH-domains of
Fig. 4. PBP10 treatment followed by its removal in PIP-kinase-overexpressing cells does not increase PI 3,4,5-P3. 3T3-L1 adipocytes were infected with a recombinant
adenovirus that expresses the PH-domains of GRP1 tagged with EGFP. For overexpressing PIP-kinase, cells were co-infected with a recombinant adenovirus that
expresses Myc-tagged human type 1α PIP-kinase (PIPK). Cells were left untreated or treated either with 1 nM insulin or 40 μM PBP10 for 15 min. Cells
overexpressing PIP-kinase were washed with the medium after PBP10 treatment, and incubated in the medium for additional 20 min. The subcellular localization of
the PH-domains of GRP1 is shown. Cells overexpressing PIP-kinase were identified by staining for the Myc-tag. Images were taken by deconvolution microscopy in
sections taken through the middle of the cells. Similar results were obtained from two other independent experiments.
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higher level of glucose uptake than cells stimulatedwith 1 nM insulin
(Fig. 2F).
These results suggest that PI 4,5-P2 acts directly to activate
GLUT4 and not as a source of PI 3,4,5-P3.
3.5. Intact F-actin is required for PI 4,5-P2-dependent and
insulin-dependent GLUT4 activation
One of the cellular effects that are regulated by PI 4,5-P2 is
F-actin remodeling [48]. Thus, to reveal the signal transduction
pathway downstream of PI 4,5-P2 in activating GLUT4, we
next investigated an involvement of F-actin in GLUT4
activation. Previous studies indicate a requirement of F-actin
for GLUT4 translocation [7,49–52]. Thus, we first treated 3T3-
L1 adipocytes with PBP10 to recruit GLUT4 to the plasma
membrane in an inactive form. Further treatment of cells either
with latrunculin A to depolymerize F-actin or with jasplakino-Fig. 3. Increased glucose uptake by PI 4,5-P2 replenishment after PBP10 treatment is
or 3T3-L1 adipocytes expressing HA-GLUT4-EGFP (B) were infected either with co
human type 1α PIP-kinase (PIPK). Cells were then either left untreated or treated with
were, then, washed with the medium and incubated in the medium for 20 min. (A
representative image from three independent experiments is shown. For quantifying t
from three independent experiments are shown. N.S., not significant. (B) Cells were i
exposed at the cell surface was quantified as described in Materials and methods. The
each cell was measured. The average value±S.E. obtained from three independen
significant. (C) Membrane sheets were prepared and stained for GLUT1. A represenlide to stabilize F-actin, in the presence of PBP10, did not affect
the amount of GLUT4 exposed at the cell surface (Fig. 5A).
Therefore, a comparison of glucose uptake between cells treated
with the carrier DMSO and cells treated either with latrunculin
A or with jasplakinolide after PBP10-pretreatment reflects the
effect of inhibiting F-actin remodeling on GLUT4 activation at
the plasma membrane.
As shown in Fig. 5B, the increased glucose uptake induced
by PBP10 treatment followed by its removal in PIP-kinase-
overexpressing cells was completely abolished by latrunculin
A, and partially but significantly inhibited by jasplakinolide.
Thus, GLUT4 activation induced by PI 4,5-P2 replenishment
requires intact F-actin remodeling.
We also investigated an involvement of F-actin remodeling
in GLUT4 activation downstream of insulin stimulation. In our
previous observation, insulin-stimulated GLUT1 translocation
was almost undetectable in PBP10-pretreated cells [30]. Thus,
the increased glucose uptake by insulin stimulation in PBP10-not attributable to recruitment of GLUT4 or GLUT1. 3T3-L1 adipocytes (A, C)
ntrol LacZ adenovirus (control) or with recombinant adenovirus for expressing
100 nM insulin or with 40 μM PBP10 for 15 min. For washing out PBP10, cells
) Membrane sheets were prepared as described in Materials and methods. A
he amount of GLUT4 in the membrane sheets, the average values±S.E. obtained
mmunostained for the HA-tag without permeation and the amount of the HA-tag
amount of the HA-tag on the cell surface per the amount of EGFP expressed in
t experiments, in which at least 20 cells were counted, are shown. N.S., not
tative image out of three independent experiments is shown.
Fig. 5. GLUT4 activation requires intact F-actin remodeling. (A–B) 3T3-L1
adipocytes were electroporated with HA-GLUT4-EGFP plasmids (A) or were
infected either with control adenovirus or with recombinant adenovirus for
expressing human type 1α PIP-kinase (PIPK) (B). Cells were first treated with
40 μM PBP10 for 15 min to bring GLUT4 in an inactive form to the plasma
membrane. Then, in the presence of PBP10, cells were treated for 30 min either
with vehicle (DMSO), 20 μM latrunculin A (Lat A) to depolymerize F-actin, or
20 μM jasplakinolide (JAS) to stabilize F-actin. (A) Cells were immunostained
for the HA-tag without permeation and the amount of the HA-tag exposed at the
cell surface was quantified as described in Materials and methods. The amount
of the HA-tag on the cell surface per the amount of EGFP expressed in each cell
was counted, and the average value for cells treated with PBP10 and DMSOwas
set as 100%. The average value±S.E. obtained from three independent
experiments, in which at least 20 cells were counted, are shown. N.S., not
significant. (B) After the treatment described above, cells were washed to
remove PBP10, but kept incubated either with DMSO, latrunculin A, or
jasplakinolide for 20 min. 2-deoxy-D-glucose uptake was measured. Data are
mean±S.E., and are expressed as fold increases of glucose uptake in control
cells infected by control LacZ adenovirus and left untreated. #p<0.01; *p<0.05
C–D. 3T3-L1 adipocytes were first left untreated (−) or treated with 40 μM
PBP10 for 15 min to bring GLUT4 in an inactive form to the plasma membrane.
Then, in the presence of PBP10, cells were treated either with DMSO, 20 μM
latrunculin A (Lat A) or 20 μM jasplakinolide (JAS) for 30 min, followed by
insulin stimulation for 15 min in the presence of PBP10 and either DMSO,
latrunculin A or jasplakinolide. 2-deoxy-D-glucose uptake was measured. Data
are mean±S.E., and are expressed as fold increases of glucose uptake in control
cells treated with DMSO only. #p<0.01. Similar results were obtained from two
other independent experiments for B–D, respectively.
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GLUT4. Both latrunculin A and jasplakinolide significantly
attenuated glucose uptake through GLUT4 that was activated
by insulin (Fig. 5C and D). These results suggest that GLUT4
activation downstream of insulin stimulation also depends on F-
actin remodeling.4. Discussion
4.1. PI 4,5-P2-dependent increase in the intrinsic glucose
transport activity of GLUT4
Evidence for GLUT4 activation as a separate step from
GLUT4 translocation/insertion to the plasma membrane during
stimulation of glucose transport through GLUT4 has been
suggested by previous studies (reviewed in [53,54]). However,
attempts to identify the molecular mechanism of GLUT4
activation have been less successful than those to identify the
mechanism of GLUT4 translocation/insertion. SB203580, an
inhibitor of p38 MAPK, was reported to inhibit glucose
transport without affecting insulin-induced GLUT4 recruitment
to the plasma membrane [27]. However, a recent finding
demonstrates that SB203580 inhibits the glucose transport
activity of GLUT4 independent of inhibiting signal transduction
by p38 MAPK [55]. In our previous report, we induced GLUT4
translocation by a phosphoinositide-binding peptide (PBP10),
placing the extracellular domain of GLUT4 at the cell surface
[30]. This GLUT4, despite its proper insertion into the plasma
membrane, did not transport glucose. PBP10 did not influence
the glucose transport activity of GLUT4, once GLUT4 was
recruited to the plasma membrane and was fully activated by
insulin before challenging with PBP10 [30]. Thus, the inability
of PBP10 to increase glucose uptake is not due to its direct
inhibition of GLUT4, and PBP10 provides a suitable condition
to analyze the signal transduction to activate GLUT4 by
completely separating it from that of GLUT4 recruitment.
Although onceGLUT4 is fully activated by insulin stimulation,
PBP10 does not influence the glucose transport activity ofGLUT4,
pretreatment of cells with PBP10 before insulin stimulation caused
an attenuated glucose transport [30]. One possible explanation is
the inhibitory effect of PBP10 on insulin-induced GLUT1 translo-
cation [30]. However, this is unlikely to account for the attenuated
glucose uptake, since we failed to detect GLUT1 translocation that
could explain the increased, although attenuated, glucose transport
in cells pretreated with PBP10 followed by insulin stimulation
[30]. Thus, we came to hypothesize that PBP10 not only lacks an
ability to activate GLUT4, but also has an inhibitory effect on
insulin signal transduction to activate GLUT4, presumably due to
the ability of PBP10 to bind phosphoinositide. As we expected,
PBP10 displaced the PH-domain of PLCδ1 from the plasma
membrane, which requires binding to PI 4,5-P2 for its plasma
membrane localization (Fig. 1), demonstrating the affinity of
PBP10 toward PI 4,5-P2 in the plasma membrane is high enough
to affect at least some PI 4,5-P2-dependent signaling events. Based
on this observation, we replenished PI 4,5-P2 in 3T3-L1 adipo-
cytes that were pretreated with PBP10, and demonstrated that the
glucose transport activity of GLUT4 was increased (Figs. 2, 3).
Although our previous data suggest an involvement of PI 3-kinase
in GLUT4 activation [30], we demonstrated that GLUT4 acti-
vation by PI 4,5-P2 replenishment was not accompanied by trans-
location of the PI 3,4,5-P3-specific PH-domains of GRP1 (Figs.
2F, 4). Thus, production of PI 3,4,5-P3, locally or at a whole cell
level, from the replenished PI 4,5-P2 is unlikely to explain the
mechanism of GLUT4 activation. Instead, our data suggest that PI
897M. Funaki et al. / Biochimica et Biophysica Acta 1763 (2006) 889–8994,5-P2 in the plasmamembrane functions as a secondmessenger in
GLUT4 activation.
Since PI 4,5-P2-dependent signaling events downstreamof PI 3-
kinase activation have been suggested in other systems [56–60],
future studies should be directed to investigate whether or not PI
4,5-P2 transmits a GLUT4 activation signal downstream of PI 3-
kinase.
4.2. The source of PI 4,5-P2 to regulate glucose transport
through GLUT4
In order to increase glucose uptake through GLUT4, GLUT4
has to go through multiple steps that need to be coordinated;
translocation to the plasma membrane, insertion into the plasma
membrane, and activation at the plasma membrane. Although the
molecular mechanism of GLUT4 translocation and insertion by
PBP10 treatment is still not known, PI 4,5-P2 is masked from its
binding partners in the presence of PBP10 (Fig. 1), when PBP10
causes GLUT4 translocation and insertion. Thus, one possible
mechanism of GLUT4 translocation and insertion is a loss of PI
4,5-P2-binding from some signaling molecule(s), whereas our
data indicate PI 4,5-P2 is required for GLUT4 activation. Even if
this is the case, the apparently contradictory signal transduction is
still plausible, since recent reports implicate compartmentalization
of PI 4,5-P2. PI 4,5-P2 is reported to distribute unevenly in the
plasma membrane [61]. Some growth factor signaling is found to
utilize PI 4,5-P2 selectively from a detergent-insoluble membrane
rafts [62,63]. Thus, it is possible for agonists to coordinately
induceGLUT4 translocation, insertion and activation by selective-
ly signaling through compartmentalized PI 4,5-P2. Since GLUT4
translocation and insertion into the plasmamembrane are followed
by GLUT4 activation in the plasma membrane [30], it is also
possible that a biphasic change in the cellular amount of PI 4,5-P2
coordinates these cellular events. Namely, a transient reduction in
the cellular amount of PI 4,5-P2 may cause GLUT4 translocation
and insertion, while increased amount of PI 4,5-P2 later may
induceGLUT4 activation. Platelets stimulatedwith thrombin have
been known to exhibit a biphasic change in the cellular amount of
PI 4,5-P2 [64], although this has not been reported in insulin
stimulation as yet. Further investigations are required to address
these questions.
4.3. The molecular mechanism of GLUT4 activation
downstream of PI 4,5-P2
The increased glucose uptake through GLUT4 by replenishing
PI 4,5-P2 was significantly impaired by inhibiting F-actin remo-
deling (Fig. 5B). Although F-actin remodeling has been shown to
be involved in GLUT4 translocation [50], the impaired glucose
uptake is due to an impaired GLUT4 activation, since both lat-
runculin A and jasplakinolide were added to the medium after
GLUT4 was inserted into the plasma membrane in an inactive
form by PBP10, and latrunculin A and jasplakinolide did not
affect the amount of GLUT4 exposed at the cell surface (Fig. 5A).
Thus, an intact F-actin remodeling is required for PI 4,5-P2-
dependent GLUT4 activation. At this moment, the mechanism of
F-actin-dependent GLUT4 activation is unclear. PI 4,5-P2-dependent F-actin remodeling may recruit GLUT4-activating
molecules to the plasma membrane just as it recruits GLUT4-
containing vesicles. Alternatively, PI 4,5-P2-dependent F-actin
remodeling may modify the microenvironment of GLUT4 in the
plasma membrane so that GLUT4 has better access to GLUT4-
activating molecules. Further studies are required on the mecha-
nismofGLUT4 activation downstreamof PI 4,5-P2-dependent F-
actin remodeling.
Insulin-induced GLUT4 activation in the plasma membrane
requires an intact F-actin remodeling (Fig. 5C, D). Since PI 4,5-
P2 is an important regulator of F-actin remodeling [48], it is
possible that insulin stimulation activates GLUT4 by way of PI
4,5-P2 and F-actin remodeling. Future studies should be di-
rected to address whether or not PI 4,5-P2 is playing a role in
GLUT4 activation by insulin stimulation.
In conclusion, we provide evidence that GLUT4 that has
translocated to and inserted into the plasma membrane in an
inactive form can be activated to initiate glucose transport by
replenishing PI 4,5-P2, which causes F-actin remodeling. These
data suggest that PI 4,5-P2 functions as a second messenger in
addition to serving as a substrate for PI 3,4,5-P3 production in
GLUT4 activation.
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